# Comparing Semaglutide and Tirzepatide: Insights from the SUSTAIN-6 Trial > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/sustain-6-cardiovascular-outcomes-trial-insights/ > **Published:** 2026-06-08T01:27:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:05:24-04:00 > **Clinical Summary:** Explore the SUSTAIN-6 cardiovascular outcomes trial highlighting semaglutide's benefits and tirzepatide's profile in type 2 diabetes management. --- GLP-1 Clinical Relevance  #52Moderate Clinical Relevance  Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News  |  CED Clinic Clinical TrialCardiovascular Outcomes StudyType 2 DiabetesSemaglutideEndocrinologyAdults with Type 2 DiabetesCardiovascular Risk ReductionGLP-1 Receptor Agonist MechanismTirzepatide ComparisonHeart Disease PreventionSUSTAIN-6 TrialMetabolic Medicine Why This Matters Family medicine clinicians require evidence-based comparative data on GLP-1 agents to optimize cardiovascular risk reduction in their patient populations, as semaglutide and tirzepatide demonstrate distinct mechanistic profiles that may yield differential outcomes in primary prevention. SUSTAIN-6 and subsequent trials provide the foundational evidence needed to inform treatment selection when balancing cardiovascular benefits against individual patient factors, tolerability, and comorbidity profiles. Understanding these comparative efficacy differences allows clinicians to align therapy choice with specific patient phenotypes rather than using a one-size-fits-all approach to GLP-1 prescribing. Clinical Summary SUSTAIN-6 was a cardiovascular outcomes trial that enrolled over 3,000 patients to evaluate semaglutide’s effects on major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk. The trial demonstrated that once-weekly subcutaneous semaglutide reduced the composite outcome of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26 percent compared to placebo. This reduction was consistent across multiple subgroups and represented a significant advancement in demonstrating class-level cardiovascular benefit for GLP-1 receptor agonists beyond glucose lowering alone. Tirzepatide, as a dual GIP and GLP-1 receptor agonist, represents a pharmacologically distinct mechanism compared to semaglutide’s selective GLP-1 agonism. While tirzepatide has demonstrated superior glycemic control and weight reduction in comparative trials with semaglutide, the cardiovascular outcomes data for tirzepatide comes from post-hoc analyses and shorter-term [safety monitoring](https://cedclinic.com/cannabis-liver-interactions-study-insights/) rather than dedicated large-scale cardiovascular outcomes trials comparable to SUSTAIN-6. Current evidence suggests both agents provide cardiovascular benefit, though the magnitude and clinical profile may differ based on their distinct receptor pharmacology. For prescribers, the established cardiovascular benefit demonstrated in SUSTAIN-6 provides robust evidence supporting semaglutide’s use in patients with type 2 diabetes who have concomitant cardiovascular disease or significant cardiovascular risk factors. The choice between semaglutide and tirzepatide should consider individual patient factors including glycemic targets, weight loss goals, tolerability profile, and the strength of available cardiovascular outcomes evidence when making treatment decisions. Clinical Takeaway Clinical Takeaway: Semaglutide demonstrated a 26% reduction in major adverse cardiovascular events in the SUSTAIN-6 trial, establishing its cardiovascular benefit in type 2 diabetes patients with established heart disease or high cardiovascular risk. Tirzepatide, as a dual GLP-1 and GIP receptor agonist, shows superior glycemic control and weight loss compared to semaglutide, though long-term cardiovascular outcomes data remain limited. Current evidence supports semaglutide as the preferred agent when cardiovascular risk reduction is the primary treatment goal, while tirzepatide may be considered when glycemic control and weight loss are prioritized in lower-risk patients. In your practice, discuss with patients that semaglutide’s proven heart benefits may warrant selection despite tirzepatide’s stronger weight loss profile, and plan for cardiovascular outcomes data on tirzepatide within the next 2-3 years to inform future comparative decisions. Dr. Caplan’s Take “While both semaglutide and tirzepatide have demonstrated meaningful cardiovascular benefits in their respective trials, the clinical evidence suggests they operate through somewhat different mechanistic pathways, with semaglutide’s cardiovascular benefits most robustly established in the SUSTAIN-6 population of patients with established cardiovascular disease. When counseling patients about medication selection, I emphasize that tirzepatide’s dual GIP/GLP-1 mechanism may offer superior glycemic control and weight loss, but the long-term cardiovascular outcomes data are still maturing compared to semaglutide’s track record. The practical implication for my practice is that I tend to preferentially select semaglutide for patients with a history of myocardial infarction or stroke, while reserving tirzepatide for metabolically complex patients without established vascular disease who benefit from its more potent weight and glucose reduction. Ultimately, both Clinical Perspective Semaglutide has established cardiovascular outcome reduction through the SUSTAIN-6 trial (demonstrating 26% MACE reduction), while tirzepatide’s cardiovascular profile remains under investigation in ongoing trials, creating a meaningful distinction in risk stratification for patients with established atherosclerotic disease or multiple cardiac risk factors. Given that GLP-1 monotherapy maintains robust CV benefit data while dual GLP-1/GIP agonists prioritize weight loss and glycemic control, clinicians should systematically assess baseline cardiovascular disease burden to determine whether proven SUSTAIN-6 benefit (semaglutide) versus superior metabolic outcomes (tirzepatide) better aligns with individual patient phenotypes. Concrete action: document cardiovascular disease history in all new GLP-1 candidates and preferentially sequence semaglutide in those with prior MI, stroke, or established coronary disease until tirzepatide’s cardiovascular outcomes trials provide equivalent evidence. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20GLP-1%20Cardiovascular%20Benefits%3A%20%3Cb%3ESemaglutide%20vs.%20Tirzepatide%3C%2Fb%3E%20%7C%20PlexusDx%20%40drcaplan&url=https%3A%2F%2Fplexusdx.com%2Fblogs%2Flearn%2Fwhich-glp-1-is-best-for-cardiovascular-benefit-plexusdx)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fplexusdx.com%2Fblogs%2Flearn%2Fwhich-glp-1-is-best-for-cardiovascular-benefit-plexusdx)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20GLP-1%20Cardiovascular%20Benefits%3A%20%3Cb%3ESemaglutide%20vs.%20Tirzepatide%3C%2Fb%3E%20%7C%20PlexusDx%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fplexusdx.com%2Fblogs%2Flearn%2Fwhich-glp-1-is-best-for-cardiovascular-benefit-plexusdx)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [Google Alert – (“Ozempic vs Wegovy” OR “Mounjaro vs Ozempic” OR “GLP-1 vs diet” OR “weight loss drugs vs surgery” OR “semaglutide vs tirzepatide”)](https://plexusdx.com/blogs/learn/which-glp-1-is-best-for-cardiovascular-benefit-plexusdx) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) Table of Contents - [FAQ](#FAQ)[What is the difference between semaglutide and tirzepatide?](#What_is_the_difference_between_semaglutide_and_tirzepatide) - [Do these medications help protect the heart?](#Do_these_medications_help_protect_the_heart) - [What was the SUSTAIN-6 trial and why does it matter?](#What_was_the_SUSTAIN-6_trial_and_why_does_it_matter) - [Am I a candidate for GLP-1 therapy if I don’t have diabetes?](#Am_I_a_candidate_for_GLP-1_therapy_if_I_dont_have_diabetes) - [How quickly will I see heart benefits from these medications?](#How_quickly_will_I_see_heart_benefits_from_these_medications) - [Does tirzepatide work better than semaglutide for the heart?](#Does_tirzepatide_work_better_than_semaglutide_for_the_heart) - [What are the common side effects I should expect?](#What_are_the_common_side_effects_I_should_expect) - [Can I stop taking these medications once I reach my goals?](#Can_I_stop_taking_these_medications_once_I_reach_my_goals) - [Are these medications safe for people with a history of thyroid cancer?](#Are_these_medications_safe_for_people_with_a_history_of_thyroid_cancer) - [How often do I need to take these medications?](#How_often_do_I_need_to_take_these_medications) - [Related](#Related) ## FAQ #### What is the difference between semaglutide and tirzepatide? Semaglutide works by mimicking one hormone called GLP-1, while tirzepatide mimics two hormones called GLP-1 and GIP. Both medications help control blood sugar and weight, but tirzepatide affects the body through two different pathways, which may produce stronger effects in some patients. #### Do these medications help protect the heart? Yes, both semaglutide and tirzepatide have been shown in [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) to reduce the risk of heart attacks and strokes in patients with type 2 diabetes and cardiovascular disease. These benefits appear to go beyond just lowering blood sugar. #### What was the SUSTAIN-6 trial and why does it matter? SUSTAIN-6 was a major [clinical study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) that enrolled over 3,000 patients to test whether semaglutide could prevent heart problems in people with diabetes. This trial provided strong evidence that the medication reduces serious cardiovascular events like heart attacks and strokes. #### Am I a candidate for GLP-1 therapy if I don’t have diabetes? GLP-1 medications are approved for type 2 diabetes and [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/), but your doctor may consider them for other reasons based on your personal health situation, including family history of heart disease or existing cardiovascular conditions. You should discuss your individual risk factors with your physician. #### How quickly will I see heart benefits from these medications? The cardiovascular benefits shown in major trials typically take months to years to fully develop, though weight loss and blood sugar improvements may happen within weeks. The heart protection builds over time as your metabolism and cardiovascular risk factors improve. #### Does tirzepatide work better than semaglutide for the heart? Both medications have shown cardiovascular benefits in clinical studies, though direct comparison data is still emerging. Your doctor can help determine which medication is better suited to your specific health needs based on your medical history and risk factors. #### What are the common side effects I should expect? The most common [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) are nausea, vomiting, and constipation, which typically occur when starting the medication or increasing the dose. These effects often improve over time as your body adjusts to the medication. #### Can I stop taking these medications once I reach my goals? These medications work best when taken long-term because benefits like weight loss and cardiovascular protection tend to decrease when you stop taking them. Stopping should always be done under your doctor’s supervision based on your individual situation. #### Are these medications safe for people with a history of thyroid cancer? Semaglutide and tirzepatide are not recommended for patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. You must inform your doctor about any thyroid cancer history before starting these medications. #### How often do I need to take these medications? Both semaglutide and tirzepatide are injected once per week under the skin, making them convenient compared to daily pills. Your doctor will show you how to give yourself the injection, and many patients find the weekly schedule easier to remember than daily medications. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Semaglutide vs Tirzepatide: Efficacy & Safety](https://cedclinic.com/semaglutide-vs-tirzepatide-cardiovascular-outcomes/) Review the comparative efficacy and safety profiles of semaglutide and tirzepatide in managing type 2 diabetes and cardiovascular risk. [Learn More](https://cedclinic.com/semaglutide-vs-tirzepatide-cardiovascular-outcomes/) [GLP-1 Diabetes Cardiovascular Outcomes: CagriSema vs Tirzepatide Trial](https://cedclinic.com/cagrisema-vs-tirzepatide-trial-glp-1-diabetes-outcomes/) Explore detailed cardiovascular outcomes from trials comparing GLP-1 receptor agonists including semaglutide and tirzepatide. [Explore Study](https://cedclinic.com/cagrisema-vs-tirzepatide-trial-glp-1-diabetes-outcomes/) [GLP-1 Receptor Agonists: Clinical Evidence and CV Outcomes](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Understand the broader clinical evidence supporting cardiovascular benefits of GLP-1 receptor agonists in diabetes care. [Read More](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).